Skip Navigation Links
Text Size


The TS Alliance administers the TS Alliance Rothberg Courage Award in Research, which was established by members of the Rothberg family to serve as a catalyst for innovative research to find treatments and a cure for TSC. The Rothberg Courage Award in Research recognizes outstanding scientific merit applied directly to TSC and provides important funding to increase the TS Alliance's capacity to accelerate research.

Rothberg Courage Awards are intended to provide funding for an established independent researcher, e.g., tenured faculty or an equivalent level at a research institution or company.  The award may support laboratory supplies, personnel costs, services, or equipment necessary to conduct the proposed research.  The TS Alliance fully supports collaborative projects between co-investigators, but only one investigator may be considered the “Principal Investigator” for the purpose of applying through proposalCENTRAL.

  • Duration: up to three years (can be shorter if appropriate for the project)
  • Budget limits (can be less if appropriate for the project):
    • Maximum total costs of $100,000 per year ($300,000 total) inclusive of both direct and indirect costs.
    • No more than 10 percent of the total costs ($10,000 per year or $30,000 total) may be applied to indirect costs.
    • Up to $1,500 may be included for travel expenses to attend a relevant scientific meeting.
  • The TS Alliance Rothberg Award for Courage in Research was established by members of the Rothberg family to serve as a catalyst for innovative research to find treatments and a cure for TSC.  This award recognizes and supports outstanding scientific research directed at finding a cure for TSC.  Successful proposals will be those that address one or more of the following:
    • Generate preclinical data testing the ability of a biomarker to better or more rapidly measure treatment effect that will enable more robust and efficient clinical studies.
    • Develop an animal or cellular model that is superior to existing preclinical models for increasing confidence that potential treatments are likely to be effective in humans and determining the dose and duration of treatment required for testing in humans.
    • Test hypotheses regarding mechanisms affecting tumor growth specific to TSC, e.g., understanding why LAM occurs primarily in women or learning why cardiac rhabdomyomas often regress at a young age.
    • Identify an existing non-rapalog molecule (or combination of molecules) that has been previously safely administered to humans, or a new non-drug intervention, that eliminates TSC-related tumors in preclinical models rather than only shrinking or stabilizing tumor growth.

Please see for key dates and information on the application process.

Courage Awards -- FY 2012

Mustafa Sahin, MD, PhD
Children’s Hospital Boston, Boston, MA
TSC Neurocognitive Clinical Trial Recruitment Acceleration Award

Darcy Krueger, MD, PhD
Cincinnati Children’s Hospital and Medical Center, Cincinnati, OH
TSC Neurocognitive Clinical Trial Recruitment Acceleration Award

Courage Awards -- FY 2011

Elizabeth Henske, MD
Brigham and Women’s Hospital, Boston, MA
Targeting Autophagy and Cellular Metabolism for the Treatment of TSC

John Bissler, MD
Cincinnati Children’s Hospital and Medical Center, Cincinnati, OH
MRI-Guided High Intensity Focused Ultrasound for TSC-Associated Renal and Pulmonary Disease

Hope Northrup, MD
University of Texas Health Science Center at Houston, Houston, TX
Identifying Additional Gene(s) That Cause Tuberous Sclerosis Complex by Whole Genome Sequencing

Courage Awards -- FY 2010

Mustafa Sahin, MD, PhD
Children’s Hospital, Harvard Medical School, Boston, MA
TSC Neurocognitive Clinical Trial

Robert and Lisa Moss
Seizure Tracker, LLC, Alexandria, VA
Development and Implementation of an Epilepsy Clinical Trial Tool

Courage Awards -- FY 2007-FY 2009

Frank McCormack, MD & Bruce Trapnell, MD 

University of Cincinnati, Cincinnati, OH 


Courage Awards -- FY 2002-FY 2005

John Blenis, PhD
Lewis Cantley, PhD
Iswar Hariharan, MBBS, PhD
David Kwiatkowski, MD, PhD
Timothy Mitchison, PhD

Harvard Medical School and Brigham & Women’s Hospital, Boston, MA
Role of the TSC1/2 Complex in Regulation of the mTOR Pathway

David Austin, PhD
Yale University, New Haven, CT
Screening of Potential Therapeutics for TSC

Tian Xu, PhD
Yale University, New Haven, CT
Role of the TSC/Insulin Signaling Pathway in the Pathogenesis of TSC

Elizabeth Petri Henske, MD
Fox Chase Cancer Center, Philadelphia, PA
Effects of Estrogen and Progesterone on Angiomyolipoma Growth and Migration

  Skip Navigation Links
Find a Local Branch
Find a Global Alliance
Become a Volunteer
Become a Member
Government Outreach
Connect With Others
Ways to Give
Your Impact
Facebook YouTube Google+ Twitter TSAlliance Support Linkedin Instagram
Make a Donation to the Tuberous Sclerosis Alliance

Your Journey with TSC: You Are Not Alone
Tuberous Sclerosis Alliance Overview
La Esclerosis Tuberosa (Spanish Intro to TSC)

What is TSC?
How is TSC Diagnosed?
Signs of TSC
Genetics of TSC

Living with TSC
Family Support
Adult Resources

TSC Connect
Brochures & Booklets
Information Sheets
Life Stages Guides & Personal Journals

Perspective Magazine Archives
TSC Clinics

TS Alliance Grants Program
Other TSC Funding Opportunities
TSC Alert Newsletter Archives
Clinical Trials
TSC Natural History Database
Research Resources
International Scientific Advisory Board

Tuberous Sclerosis Alliance Online CommunityTuberous Sclerosis Alliance Support Community  

Great NonProfits 2016 National Organization for Rare Disorders Rare Disease Report GuideStar Exchange Gold Participant The Arc Combined Federal Campaign